Transient T cell depletion causes regression of melanoma metastases

详细信息    查看全文

• 作者：Mary Ann Rasku (1)
  Amy L Clem (1)
  Sucheta Telang (1)
  Beverly Taft (1)
  Kelly Gettings (1)
  Hana Gragg (1)
  Daniel Cramer (1)
  Sheron C Lear (2)
  Kelly M McMasters (3)
  Donald M Miller (1)
  Jason Chesney (1)
  
• 刊名：Journal of Translational Medicine
• 出版年：2008
• 出版时间：December 2008
• 年：2008
• 卷：6
• 期：1
• 全文大小：4237KB
• 参考文献：1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ: Cancer statistics, 2005. / CA Cancer J Clin 2005,55(1):10-0. CrossRef
  2. Thompson JF, Scolyer RA, Kefford RF: Cutaneous melanoma. / Lancet 2005,365(9460):687-01.
  3. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. / J Clin Oncol 1999,17(7):2105-116.
  4. Keilholz U, Conradt C, Legha SS, Khayat D, Scheibenbogen C, Thatcher N, Goey SH, Gore M, Dorval T, Hancock B, Punt CJ, Dummer R, Avril MF, Brocker EB, Benhammouda A, Eggermont AM, Pritsch M: Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. / J Clin Oncol 1998,16(9):2921-929.
  5. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. / J Clin Oncol 1996,14(1):7-7.
  6. Curiel TJ: Tregs and rethinking cancer immunotherapy. / J Clin Invest 2007,117(5):1167-174. CrossRef
  7. Jones E, Dahm-Vicker M, Golgher D, Gallimore A: CD25+ regulatory T cells and tumor immunity. / Immunol Lett 2003,85(2):141-43. CrossRef
  8. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H: Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. / Blood 2005,105(7):2862-868. CrossRef
  9. Jones E, Dahm-Vicker M, Simon AK, Green A, Powrie F, Cerundolo V, Gallimore A: Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. / Cancer Immun 2002, 2:1.
  10. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN: Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. / J Exp Med 2004,200(6):771-82. CrossRef
  11. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E: Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. / Cancer Res 1999,59(13):3128-133.
  12. Shimizu J, Yamazaki S, Sakaguchi S: Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. / J Immunol 1999,163(10):5211-218.
  13. Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ: Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. / J Exp Med 2001,194(6):823-32. CrossRef
  14. Viguier M, Lemaitre F, Verola O, Cho MS, Gorochov G, Dubertret L, Bachelez H, Kourilsky P, Ferradini L: Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. / J Immunol 2004,173(2):1444-453.
  15. Frankel AE, Surendranathan A, Black JH, White A, Ganjoo K, Cripe LD: Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia. / Cancer 2006,106(10):2158-164. CrossRef
  16. Berger CL, Tigelaar R, Cohen J, Mariwalla K, Trinh J, Wang N, Edelson RL: Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells. / Blood 2005,105(4):1640-647. CrossRef
  17. McDermott DF, Mier JW, Lawrence DP, van den Brink MR, Clancy MA, Rubin KM, Atkins MB: A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma. / Clin Cancer Res 2000,6(6):2201-208.
  18. Legha SS, Ring S, Eton O, Bedikian A, Buzaid AC, Plager C, Papadopoulos N: Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. / J Clin Oncol 1998,16(5):1752-759.
  19. Peggs KS, Quezada SA, Korman AJ, Allison JP: Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. / Curr Opin Immunol 2006,18(2):206-13. CrossRef
  20. Wu Z, Bensinger SJ, Zhang J, Chen C, Yuan X, Huang X, Markmann JF, Kassaee A, Rosengard BR, Hancock WW, Sayegh MH, Turka LA: Homeostatic proliferation is a barrier to transplantation tolerance. / Nat Med 2004,10(1):87-2. CrossRef
  21. Dummer W, Niethammer AG, Baccala R, Lawson BR, Wagner N, Reisfeld RA, Theofilopoulos AN: T cell homeostatic proliferation elicits effective antitumor autoimmunity. / J Clin Invest 2002,110(2):185-92.
  22. Hu HM, Poehlein CH, Urba WJ, Fox BA: Development of antitumor immune responses in reconstituted lymphopenic hosts. / Cancer Res 2002,62(14):3914-919.
  23. Barnett B, Kryczek I, Cheng P, Zou W, Curiel TJ: Regulatory T cells in ovarian cancer: biology and therapeutic potential. / Am J Reprod Immunol 2005,54(6):369-77. CrossRef
  24. Attia P, Maker AV, Haworth LR, Rogers-Freezer L, Rosenberg SA: Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. / J Immunother 2005,28(6):582-92. CrossRef
  25. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, Zhang A, Dahm P, Chao N, Gilboa E, Vieweg J: Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. / J Clin Invest 2005,115(12):3623-633. CrossRef
  
• 作者单位：Mary Ann Rasku (1)
  Amy L Clem (1)
  Sucheta Telang (1)
  Beverly Taft (1)
  Kelly Gettings (1)
  Hana Gragg (1)
  Daniel Cramer (1)
  Sheron C Lear (2)
  Kelly M McMasters (3)
  Donald M Miller (1)
  Jason Chesney (1)
  
  1. Molecular Targets Program, James Graham Brown Cancer Center, University of Louisville School of Medicine, Louisville, KY, USA
  2. Department of Pathology, University of Louisville School of Medicine, Louisville, KY, USA
  3. Department of Surgery, University of Louisville School of Medicine, Louisville, KY, USA
  

文摘

Background Cognate immunity against neoplastic cells depends on a balance between effector T cells and regulatory T (Treg) cells. Treg cells prevent immune attack against normal and neoplastic cells by directly suppressing the activation of effector CD4+ and CD8+ T cells. We postulated that a recombinant interleukin 2/diphtheria toxin conjugate (DAB/IL2; Denileukin Diftitox; Ontak) may serve as a useful strategy to deplete Treg cells and break tolerance against neoplastic tumors in humans. Methods We administered DAB/IL2 (12 μg/kg; four daily doses; 21 day cycles) to 16 patients with metastatic melanoma and measured the effects on the peripheral blood concentration of several T cell subsets and on tumor burden. Results We found that DAB/IL2 caused a transient depletion of Treg cells as well as total CD4+ and CD8+ T cells (< 21 days). T cell repopulation coincided with the de novo appearance of melanoma antigen-specific CD8+ T cells in several patients as determined by flow cytometry using tetrameric MART-1, tyrosinase and gp100 peptide/MHC conjugates. Sixteen patients received at least one cycle of DAB/IL2 and five of these patients experienced regressions of melanoma metastases as measured by CT and/or PET imaging. One patient experienced a near complete response with the regression of several hepatic and pulmonary metastases coupled to the de novo appearance of MART-1-specific CD8+ T cells. A single metastatic tumor remained in this patient and, after surgical resection, immunohistochemical analysis revealed MART1+ melanoma cells surrounded by CD8+ T cells. Conclusion Taken together, these data indicate that transient depletion of T cells in cancer patients may disrupt the homeostatic control of cognate immunity and allow for the expansion of effector T cells with specificity against neoplastic cells. Several T cell depleting agents are clinically available and this study provides strong rationale for an examination of their efficacy in cancer patients. Trial registration NCT00299689 (ClinicalTrials.gov Identifier).